These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 33550851)

  • 41. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies.
    Moser DK; Biddle MJ
    Crit Care Nurs Clin North Am; 2003 Dec; 15(4):423-37, vii-viii. PubMed ID: 14717387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pharmacological therapy of heart failure with reduced ejection fraction].
    Wieser M; Rhyner D; Martinelli M; Suter T; Schnegg B; Bösch C; Wigger O; Dobner S; Hunziker L
    Ther Umsch; 2018 Sep; 75(3):180-186. PubMed ID: 30145973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs.
    Hyman DA; Siebert VR; Birnbaum GD; Alam M; Birnbaum Y
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):215-221. PubMed ID: 32219664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
    Thakur V; Rankin KN; Hartling L; Mackie AS
    Cardiol Young; 2013 Aug; 23(4):568-81. PubMed ID: 23083542
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Drug treatment for chronic heart failure with reduced ejection fraction].
    Rickenbacher P
    Ther Umsch; 2011 Feb; 68(2):71-9. PubMed ID: 21271537
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.
    Zou Z; Yuan HB; Yang B; Xu F; Chen XY; Liu GJ; Shi XY
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009210. PubMed ID: 26816003
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice.
    Chin KL; Skiba M; Tonkin A; Reid CM; Liew D; Krum H; Hopper I
    Heart Fail Rev; 2016 Nov; 21(6):675-697. PubMed ID: 27465132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2015 Feb; 33(2):195-211. PubMed ID: 25485720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Khan MS; Fonarow GC; Khan H; Greene SJ; Anker SD; Gheorghiade M; Butler J
    ESC Heart Fail; 2017 Nov; 4(4):402-408. PubMed ID: 28869332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Angiotensin receptor blockers for heart failure.
    Heran BS; Musini VM; Bassett K; Taylor RS; Wright JM
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003040. PubMed ID: 22513909
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?
    Cruden NL; Newby DE
    Am J Cardiovasc Drugs; 2004; 4(6):345-53. PubMed ID: 15554719
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
    Aronow WS
    J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
    Rodgers JE; Patterson JH
    Am J Health Syst Pharm; 2001 Apr; 58(8):671-83. PubMed ID: 11329759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Angiotensin II receptor blockers in the treatment of heart failure.
    Peterson RC; Dunlap ME
    Congest Heart Fail; 2002; 8(5):246-50; 256. PubMed ID: 12368586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of angiotensin II receptor blockers in the treatment of heart failure patients.
    Theal M; Demers C; McKelvie RS
    Congest Heart Fail; 2003; 9(1):29-34. PubMed ID: 12556675
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
    Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
    J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis.
    Wang B; Wang F; Zhang Y; Zhao SH; Zhao WJ; Yan SL; Wang YG
    Lancet Diabetes Endocrinol; 2015 Apr; 3(4):263-74. PubMed ID: 25660574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploring new treatment strategies in heart failure.
    Swedberg K
    Blood Press Suppl; 2000; 1():44-8. PubMed ID: 11059637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.